Harnessing the power of urinary miRNA to detect cancer early
Detecting cancers in early stages when it is treatable
Craif has harnessed the power of miRNA in cancer pathways to detect cancer in early stages when it is still treatable. Our primary focus is pancreatic cancer, which today is often detected too late to save lives.
miSignal test can detect 7 types of cancer (pancreatic, colorectal, lung, stomach, esophagus breast, ovarian) from a simple urine draw.* available in Japan
Experienced USA Team with Proven Track Record
Chief Corporate Development Officer
20 years Life Science experience across diagnostics, medical devices and biopharma with lead or key player in six product launch teams including 11 years in diagnostics with roles Officer/Head of Commercial for early cancer detection assay, practice leader Precision Medicine at Health Advances working with molecular diagnostic companies in launch planning and pipeline prioritization, Business Development lead for early stage maternal fetal health diagnostic.
Head of Clinical Operations (Consultant)
Clinical operations executive with over 15 years experience leading IVD and medical device clinical operations teams. Co-author of peer-reviewed publications that have driven successful product launches and positive payer decisions.
Head of Program Management (Consultant)
Accomplished leader with over 20 years of assay, software, device, and systems IVD experience from R&D and validation through clinical trials, regulatory filings, commercialization, and audits (FDA and CE).
Head of Market Access
25+ years of experience in the life sciences industry, primarily as a commercial and market access executive including commercial operations leader at Genentech where he helped launch Rituxan, Herceptin and Avastin and one of the first employees at Genomic Health where he led the reimbursement effort and helped grow annual revenues to over $300M.
Head of Market Planning
Strategic business leader with over 19+ years of demonstrated expertise in innovation, strategy development, and market planning. Successfully launched novel healthcare products into global markets and diverse regulatory environments for startups and Fortune 500 companies.
Advisor providing regulatory and compliance support for US product development
Successfully guided the establishment of multiple licensed CLIA Labs and the Verification/Validation of multiple LDT clinical diagnostics including multiple analyte algorithm based tests.
Joint research results on urothelial cancer with Keio University School of Medicine presented at the 61st Annual Meeting of the Japan Society of Clinical Oncology
Craif Scientific Advisor and Co-founder Yasui’s research findings on ovarian cancer were published in Nature Communications
The Number of Medical Institution Installing miSignal®️ Achieved 300
Craif Announced New Product in miSignal®️ Series, “Remote Cancer TestTM”